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The  cuprizone  mouse  model  allows  the investigation  of  the complex  molecular  mechanisms  behind
nonautoimmune-mediated  demyelination  and  spontaneous  remyelination.  While  it is generally  accepted
that oligodendrocytes  are  speciﬁcally  vulnerable  to  cuprizone  intoxication  due  to  their  high  metabolic
demands,  a comprehensive  overview  of the  etiology  of cuprizone-induced  pathology  is  still  missing  to
date.  In this  review  we extensively  describe  the  physico-chemical  mode  of  action  of cuprizone  and  discuss
the molecular  and enzymatic  mechanisms  by  which  cuprizone  induces  metabolic  stress,  oligodendrocyte
apoptosis,  myelin  degeneration  and  eventually  axonal  and  neuronal  pathology.  In  addition,  we  describe
the dual  effector  function  of  the  immune  system  which  tightly  controls  demyelination  by effective  induc-
tion of  oligodendrocyte  apoptosis,  but  in  contrast  also paves  the  way  for fast  and  efﬁcient  remyelination
by  the  secretion  of neurotrophic  factors  and the clearance  of  cellular  and  myelinic  debris.  Finally,  weetabolic stress
euroinﬂammation
emyelination
emyelination
ultiple sclerosis
discuss  the  many  clinical  symptoms  that  can  be observed  following  cuprizone  treatment,  and  how  these
strengthened  the  cuprizone  model  as a  useful  tool  to  study  human  multiple  sclerosis,  schizophrenia  and
epilepsy.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).pilepsy
chizophrenia
ontents
1. Introduction  & historical  perspectives  . .  .  . . .  . . .  .  . . .  . . .  .  .  . . . . . .  . . . .  . . .  . .  . . .  . . . .  .  . . . . .  . . . .  . . . .  .  . . . .  . . .  . . . . . . .  .  . . .  .  . .  .  . . .  .  . . .  . .  .  .  .  . . . .  . . . . . .  .  .  .  .  . .  . . .  .  . 486
2.  CPZ-induced  metabolic  stress  predisposes  oligodendrocytes  to  apoptosis  . . .  . . .  . . . .  . . . .  .  . . . . . .  . . . . . . . .  . . . .  .  . .  . . . . . . .  . . . . . . .  . .  .  . .  . .  .  .  .  . .  . .  .  .  . . . . . . 486
2.1. Physico-chemical  behavior  of CPZ. .  . . .  . .  .  .  . . .  .  . .  .  . . . .  .  . .  .  . . .  .  .  . . . .  . . .  . . .  . . . . . . . . . .  . . .  . .  . . . . . .  .  . . . . . .  .  . . . .  . . .  .  . . . . . .  . . .  . .  . . . .  .  . . . . .  .  . .  .  . .  .  .  .  .  486
2.2.  Megamitochondria  and  oxidative  stress  .  . . . . . . .  .  . . .  . . .  . . . . . .  .  .  . . . .  . . .  .  . . .  . .  .  . . . . . .  .  . . . . .  . . .  . . . . . . . .  . .  .  . .  .  .  . . .  . . .  .  .  .  .  . .  . .  .  . . . . . . . .  .  . . .  .  .  .  .  .  . 486
2.3.  Perikaryon  and  myelin  sheath  degeneration  .  . . .  .  . . .  . . . .  . . . . . . . .  . . . . .  . . .  .  . . . . .  . . . . .  . . .  .  .  . .  .  . . . .  . . .  . . . . .  . .  . . .  .  . . . . . . .  . . . .  .  .  .  . . .  .  . . . . .  . . . .  .  .  .  .  490
2.4.  Oligodendrocyte  apoptosis  . .  . . . . . . .  . . . .  . . .  .  .  . .  .  . . .  . . . .  . . . . .  .  . .  .  . . .  . . .  . . . .  . .  .  . .  . . . . .  . . . . . . .  .  . . . . . .  . . . .  . . .  . . . .  .  . . . .  .  . .  . . . .  .  . . . . . . .  . . .  . . .  .  . .  . .  .  491
3. Neuronal  pathology  .  . . .  .  . . .  . . . .  . . .  .  . . . .  . . .  .  . .  .  .  . . .  .  . . .  . . . . . . .  . . .  . . . .  .  . . . . . . .  . . . . . . . .  .  . . .  .  . . .  . . .  . . .  . . . .  .  . . .  .  . . .  . . .  . . .  .  . . .  .  .  . . . .  . . . . .  .  .  .  .  . .  .  . .  . . . . .  . . . 491
3.1.  Neuronal  pathology  and  metabolic  coupling  between  neurons  and  astrocytes  . . . . .  .  .  . . .  . . .  . .  . . .  . .  .  . . .  . . .  .  .  . .  .  . . . .  .  . . . . . .  . . .  .  .  .  . . .  .  . . . . . . .  491
3.2.  Disturbance  of neurotransmitter  homeostasis  .  .  . . . .  . .  .  . . . . . . .  .  . . .  .  . . .  . .  . . .  . . . .  .  .  . . . .  . . .  . . .  . .  .  . . . .  .  . . .  .  . . .  . . .  .  . .  .  . . .  .  .  . . . . . .  . . .  . .  .  .  . .  .  . . . . . .  493
3.3.  Axonal  beading  . . .  .  . . .  . . . .  . . .  . . . .  .  . . .  .  . .  .  .  . .  .  .  . . .  . . .  . . .  .  .  . . . . .  .  . .  .  . . . .  .  . .  . . . . .  . . . . . . .  .  . .  .  . . . .  . . .  . . . . .  . .  . . . . . .  .  . . . .  .  . . . .  .  .  .  .  . .  .  . . . .  .  . . . .  .  . . .  . . 493
4.  Involvement  of  the immune  system  .  . . . .  . . .  .  . . .  .  . . .  . . . .  . . . . . . .  . . .  . . .  . . . .  . . .  . .  .  . . .  .  . . .  . . . . . .  . . .  .  .  . . . .  .  . . . . .  . .  .  . . . .  . . .  .  . . . .  .  . .  .  . . . . . . . . . .  .  .  . .  . .  .  . . .  . . 494
4.1. Neutrophils  . . .  . . .  . . . .  . . . .  . . .  . . . .  . . . .  .  . .  .  .  . .  .  .  . .  .  . . . . . . .  . .  .  . . . .  .  . . . . . 
4.2. Astrocytes  . .  . .  .  . . .  .  . . .  .  . .  .  .  . . . . . .  . . .  .  . . .  .  . .  .  .  . .  .  .  .  . .  . . .  .  . .  .  . . . .  .  .  .  . . .
4.3.  Microglia/macrophages.  .  .  . .  . . . . . . .  . . . .  .  . .  .  . . .  .  . . .  .  . .  . . . .  .  . . . . . .  . . .  .
4.4.  T and  B cells  . .  .  . . .  .  . . .  . . . .  . . .  . . . .  . . . .  .  . . .  . . .  .  . . .  . . . .  . . . .  . . .  . . . .  . . . . . .
∗ Corresponding author at: Bio-Imaging Lab, University of Antwerp, Campus Drie Eiken
el.:  +0032 3 2652762.
E-mail address: jelle.praet@uantwerpen.be (J. Praet).
ttp://dx.doi.org/10.1016/j.neubiorev.2014.10.004
149-7634/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article un.  .  . . . . . . . .  .  . . .  .  . . .  . . . . .  . . .  . .  .  . . .  .  . . .  . . .  . . .  .  . .  .  .  . . . . .  . . . . .  .  .  .  .  . .  .  . .  . .  . . . . .  494
 . . .  .  . . .  . .  .  . . . . . . .  . . . . .  . . .  . .  . . . . . .  . .  .  . . .  .  . . .  . . .  .  . .  .  .  .  .  .  .  . . . . . . .  .  .  .  . .  .  . .  .  .  . 494
 . . . .  . . . . .  .  . .  .  . . .  .  . . .  . . . . . . . .  . . . . . . .  . . .  . . . .  .  . . . . .  .  .  . .  .  . . . . . .  . . . .  .  .  .  . . .  . .  .  .  495
 . .  . . .  . .  . . .  . . . .  .  . . . . . .  . . . . .  . .  .  . . . . . .  .  . . . . . . .  . . . .  . . . . .  . . . .  .  .  .  . . .  . . . . . .  .  . . .  .  496
 (CDE-Uc.114), Universiteitsplein 1, 2610 Antwerp (Wilrijk), Belgium.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
486 J. Praet et al. / Neuroscience and Biobehavioral Reviews 47 (2014) 485–505
5.  Remyelination  .  . . .  . . . . . . . .  . . . .  . . .  .  . . .  .  . . . .  . . . . . . . . . .  . . . . . . . .  .  . . . . . . .  . . .  .  . . . .  .  . .  .  . . . . .  . . .  . . . .  . . . . . . .  .  . .  . . . .  .  . . . . . . .  . . . . . . .  . . . .  .  . .  .  .  .  .  .  .  . . . . . .  . . . .  . .  . .  . 496
6. Morphological  and  clinical  manifestations  after  cuprizone  intoxication  . . .  . . .  . . .  . . .  .  . . .  . . . . . .  . . . . .  . . .  .  . . . .  . . . . . . .  . .  .  . . . .  . . .  .  . .  . .  . . .  .  . .  . .  .  .  . . . . . .  . 498
7. Relevance  as  a  model  for human  diseases  . . . . . . .  .  . .  .  .  . .  .  .  . . . . . . .  . .  . . . . .  .  . .  . . . . . . .  . . . . . . .  .  . . . . . .  . . . . .  . .  .  .  .  . .  . . .  . . . . . . .  .  . . .  .  . .  . . . . . . . . .  .  . . .  .  .  .  . . . .  . . .  499
7.1.  Cuprizone  as a model  for  multiple  sclerosis  . . . .  . . .  . . . . .  . . .  . . . . . . .  .  . . .  . .  .  . . . .  . .  .  . . . . . . .  . . . . . . . . . .  . . . . .  .  . .  . . . .  . . . .  . . . . .  . . . .  .  .  . . . .  .  . . . . .  . .  .  .  .  .  499
7.2.  Cuprizone  as a model  for  epilepsy  . .  .  . . . .  . . . . . . . . . . . . . .  . . .  .  . . .  . . . .  .  . .  . . .  . .  .  . . . .  .  . .  . . . . . .  .  . . . .  . . . .  .  . . .  . . . .  . . .  . .  .  . . . . . . .  .  .  .  .  .  . . .  .  . .  . .  .  .  . . . . . .  . 500
7.3. Cuprizone  as a model  for  schizophrenia  .  . . . .  . . .  .  . . .  . . . . . . .  .  . . .  . . . . .  .  .  .  . . . . .  .  . . . . . .  .  . . . . . .  .  . . . . . .  . . . . . . .  .  . . . . . . .  . . .  . .  . . . .  .  . . . . . .  . . .  .  .  .  . .  . .  . . 500
8.  Concluding  remarks  . .  .  . . . .  .  . .  .  . . .  .  . . .  . . . . . . . . . . .  . . . .  . . . .  .  . .  . .  . .  .  . . .  .  . . . .  .  . . . . . .  .  .  .  . . .  .  .  . .  . . .  . .  .  . . . .  .  . .  . .  . .  . . .  .  . . .  . . .  .  . . .  . . .  .  . . .  .  .  . . . . .  .  . . . .  . .  . .  .  . .  . .  500
Acknowledgments  . .  .  . . .  . . . .  .  . . .  . . .  .  . . . .  . . . . . .  . . . .  . . . .  .  . .  .  . . .  .  . .  . . . . .  .  . .  . . . . .  .  .  .  . . .  . .  .  . . . . . .  .  . . . .  .  . .  .  . . .  .  . . .  . .  . . . . . .  .  . . . . . . .  . . . .  . . .  . . . . . .  .  .  .  .  . . . . . .  . 501
.  . . . .  .
1
m
W
t
M
r
s
i
t
a
t
(
p
i
t
C
t
c
t
a
r
l
3
m
a
C
d
e
e
e
a
t
m
i
e
m
n
m
b
d
(
c
i
(
r
t
m
t
d
aReferences  .  . . . . .  . . . .  . . .  . . . . . . . . . . .  . . .  .  . . .  .  . . . . . .  . . . .  . . . .  . . .  . . . .  . . . . . . .  
. Introduction & historical perspectives
Multiple sclerosis (MS) is generally accepted to be an autoim-
une demyelinating disease of the central nervous system (CNS).
hile the ﬁrst real medical descriptions of MS  date back to
he early 18th century, only little progress in understanding
S pathology was made during the 18th and 19th century as
esearch was limited to post-mortem examination of brain tis-
ue from MS  patients. During the 20th century however, several
mmune-mediated animal models for MS  were developed like
he experimental autoimmune encephalomyelitis (EAE) model
nd the Theiler murine encephalomyelitis virus model. Besides
hese, toxin-induced demyelinating models like the cuprizone
bis-cyclohexanone-oxalyldihydrazone, CPZ) model, the lysophos-
hatidyl choline injection model and the ethidium bromide
njection model are often used to investigate the molecular fac-
ors contributing to de- and remyelination. The ﬁrst description of
PZ by Gustav Nilsson dates back to 1950 following his observation
hat CPZ, which is the condensation product of oxalylhydrazide and
yclohexanone, induced a sensitive blue color reaction upon chela-
ion with copper (Cu) salts (Nilsson, 1950). The ﬁrst biomedical
pplication however, dates back to 1966 when Carlton observed
eproducible low serum Cu levels and demyelination in mice fol-
owing administration of CPZ (Carlton, 1966). During the following
 decades, CPZ was mainly used to induce demyelination in Swiss
ice, but other mice strains (Albino, BALB/c, BSVS, CD1, ICI & SJL) or
nimal species (Albino and Wistar rats, guinea pigs and Syrian and
hinese hamsters) were also known to display a variable degree of
emyelination upon CPZ intoxication (Adamo et al., 2006; Basoglu
t al., 2013; Elsworth and Howell, 1973; Franco et al., 2008; Kanno
t al., 2012; Ludwin, 1978; Skripuletz et al., 2011a; Wakabayashi
t al., 1977).
Hiremath et al. (1998) published a key study in which the vari-
bility of CPZ-induced pathology was reduced to a minimum. In
his study, it was determined that feeding 8 week old C57BL/6
ice with a 0.2% CPZ-supplemented diet for 6 weeks consistently
nduced demyelination with minimal clinical toxicity, making this
xperimental setup quickly the most used variant of the CPZ mouse
odel. Following these experiments, 2 experimental setups are
ow often used on the C57BL/6 background: (i) feeding C57BL/6
ice with a 0.2% CPZ-supplemented diet for 4–6 weeks followed
y recovery on a normal diet, resulting in the induction of acute
emyelinating lesions followed by spontaneous remyelination and
ii), feeding C57BL/6 mice with a 0.2% CPZ supplemented diet
ontinuously for 12 weeks, resulting in the induction of chron-
cally demyelinated lesions with limited remyelination capacity
Matsushima and Morell, 2001). Acute/chronic demyelination and
emyelination, as well as micro- and astrogliosis, following CPZ
reatment are represented in Fig. 1.
While the CPZ mouse model has been applied on different ani-
al  species and mouse strains during the past 4 decades, currently
his model is mainly used on mouse C57BL/6 background as repro-
ucible de- and remyelination is accompanied by microgliosis and
strogliosis. In addition, the availability of many transgenic mouse . .  .  . . . . . . . .  .  . . . . . . .  .  . . .  . .  . . .  . .  . . .  .  .  . . .  . . . .  .  . . . . . . .  .  .  . .  .  .  .  . .  . . .  .  . . . . . .  .  . .  .  501
strains on C57BL/6 background (Table 1), combined with the high
reproducibility of the CPZ model on this background, makes CPZ
intoxication a favorable model to study both acute and chronic
demyelination, as well as remyelination.
2. CPZ-induced metabolic stress predisposes
oligodendrocytes to apoptosis
While it is generally accepted that CPZ induced toxicity origi-
nates from a perturbation of the very active metabolism in OLGs, no
real consensus exists yet concerning the actual modus operandi of
CPZ. Within the following chapter, we  unify all current knowledge
concerning the biochemical and molecular events triggered by CPZ
administration, and how these eventually lead to OLG  apoptosis
and demyelination.
2.1. Physico-chemical behavior of CPZ
Cu, as a cofactor for various cuproenzymes, plays a very
important role in many cellular processes and therefore has its
concentration tightly regulated within the cell. A disturbed Cu
homeostasis can result in neurodegeneration, as for example
observed in Wilson’s and Menkes disease. Therefore, it is tempt-
ing to assume that CPZ-induced pathology originates either from Cu
buildup due to entrapment within the cell or from Cu deﬁciency due
to chelation (Rossi et al., 2004). To date, two hypotheses regarding
the physico-chemical behavior of CPZ have been investigated.
The ﬁrst hypothesis suggests that CPZ-induced pathology origi-
nates from Cu deﬁciency. The authors of this hypothesis proposed
that CPZ induces a functional Cu deﬁcit as: (i) they could not detect
CPZ in brain and liver extracts or serum samples from CPZ-treated
mice, and (ii) the chelation of Cu2+ by CPZ resulted in precipitat-
ing CPZ-Cu2+ oligomers in the gastrointestinal tract (Benetti et al.,
2010; Taylor et al., 2010b; Venturini, 1973). However, the second
hypothesis states that Cu is chelated by CPZ as Cu3+ and requires 2
CPZ molecules for each Cu atom bound. Zatta et al. (2005) proposed
that CPZ had to be present in the brain as: (i) they could detect CPZ in
blood plasma, (ii) a 5-fold increase in brain Cu concentrations after
9 months of a very mild CPZ treatment was observed due to CPZ-Cu
oligomer precipitation, and (iii) the hydrazone group of CPZ will be
partially hydralized upon binding of Cu, giving rise to the corre-
sponding hydrazide, and CPZ has to be present within the brain for
hydrazide-dependent enzyme inhibition to occur (Messori et al.,
2007).
Summarizing, the pathological effects of CPZ treatment are due
to: (i) in situ disturbance of Cu homeostasis, and (ii) a neurotoxic
effect due to enzyme inhibition. However, given the existence of
two contradictory hypotheses, further research will be required to
fully elucidate the physico-chemical behavior CPZ.2.2. Megamitochondria and oxidative stress
Suzuki (1969) was the ﬁrst to report that CPZ induces the for-
mation of megamitochondria in liver tissue of mice (Petronilli
J. Praet et al. / Neuroscience and Biobehavioral Reviews 47 (2014) 485–505 487
Fig. 1. Representative overview showing myelin content (T2 MRI  image and MBP  staining), microgliosis (IBA-1 staining) and astrogliosis (GFAP staining) at different time
points  following feeding of 8-week old female C57BL6/J mice with a 0.2% cuprizone (CPZ) supplemented diet. During acute demyelination (week 4, 4 W),  extensive microgliosis
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(nd  astrogliosis can be observed. By week 6 (6 W)  of CPZ treatment, an attempt to rem
f  CPZ for 12 weeks (12 W)  induces extensive demyelination and astrogliosis. Howe
reatment (6 W + 6 W),  extensive remyelination occurs, while both microgliosis and
nd Zoratti, 1990; Tandler and Hoppel, 1975; Wagner and Rafael,
977). While hepatic megamitochondria in C57BL/6 mice could
nly be observed following a 0.5% CPZ supplemented diet, the for-
ation of megamitochondria in OLGs was observed already after a
 week 0.2% CPZ diet (Acs and Komoly, 2012; Biancotti et al., 2008;
iremath et al., 1998). Megamitochondria formation was  however
ot observed in neurons, astrocytes, cardiac, kidney, kupfer or fat
toring cells (Asano et al., 1978; Ludwin, 1978; Tandler and Hoppel,
973; Wakabayashi et al., 1978). Recent in vitro experiments in
hich rat primary glial cell cultures were treated with CPZ provided
dditional proof that microglia, astrocytes and oligodendrocyte
recursors cells (OPCs) are unaffected by CPZ while mature OLGs
how signs of toxicity upon CPZ treatment (e.g. decreased survival
nd reduced mitochondrial transmembrane potential) (Benardais
t al., 2013; Pasquini et al., 2007).
Inhibition of ﬁssion was described as the responsible mecha-
ism for megamitochondria formation (Asano et al., 1978; Flatmark
t al., 1980; Miwa et al., 2008; Tandler and Hoppel, 1973;
akabayashi et al., 1977, 1975). However, mitochondria quickly
egained a normal morphology when CPZ treatment was halted
Flatmark et al., 1980; Tandler and Hoppel, 1973; Wakabayashiate occurs, while astrogliosis persists in the absence of microgliosis. Administration
hen mice are allowed to recover for 6 weeks on a normal diet after 6 weeks of CPZ
gliosis disappear. (Scale bars = 100 m).
et al., 1975). In vitro, mitochondria enlarge when subjected to ele-
vated levels of reactive oxygen species (ROS) and reactive nitrogen
species (RNS), eventually resulting in the formation of megami-
tochondria. Therefore, the formation of megamitochondria can be
considered as a protective measure of the cell to reduce oxidative
stress (Wakabayashi, 2002). Nonetheless, the amount of electrons
leaking from the electron transport chain (ETC), and thus O2•– pro-
duction, increases dramatically during CPZ treatment due to: (i)
an uncoupling of the oxidative phosphorylation process (Tandler
and Hoppel, 1973, 1975; Wakabayashi et al., 1975), (ii) a reduced
reaction surface (Tandler and Hoppel, 1975), (iii) differences in the
cytochrome content (Flatmark et al., 1980; Wagner and Rafael,
1977), and (iv) an inhibition of Complex I–III, Complex II–III and
Complex IV (De and Subramanian, 1982; Kimberlin et al., 1976;
Millet et al., 2009; Nelecz et al., 1982; Pasquini et al., 2007; Petronilli
and Zoratti, 1990; Venturini, 1973; Wakabayashi et al., 1978). In
contrast to these observations, Acs et al. (2013) recently described
that cuprizone treatment does indeed inhibit Complex IV activity,
but not Complex I + III or Complex II + III. Nonetheless, CPZ intox-
ication clearly imposes an increased oxidative stress on OLGs. In
addition, the factors listed below, and shown in Fig. 2, contribute
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Table 1
Overview of all transgenic mice strains to which the CPZ model has been applied and how the transgenic background inﬂuences demyelination, oligodendrocyte apoptosis,
remyelination, microgliosis and astrogliosis.
Phenotype Demyelination OLG loss Remyelination Microgliosis Astrogliosis Reference
Overexpression
GFAP-C3a More Delayed More More Ingersoll et al. (2010)
GFAP-C5a More Delayed More More Ingersoll et al. (2010)
GFAP-PDGF- Normal Normal Woodruff et al. (2004)
Upon chronic demyelination, remyelination was  improved Vana et al. (2007)
GFAP-sCrry Less Less Briggs et al. (2007)
GFAP/tTA-TRE/IFN Normal Normal Less Lin et al. (2006)
GFAP/tTA-TRE/IFN PERK+/– Normal Less Lin et al. (2006)
GFAP/tTA-TRE/IFN-PLP/Fv2E-PERK Allows inducible expression of both PERK and IFN expression Lin et al. (2014)
MBP-IFN Less Less Less Less Gao et al. (2000)
MBP-J37 golli More More More More More Paez et al. (2012)
MT1-IGF1 Normal Less Accelerated Mason et al. (2000b)
GAL-tg Less Less Zhang et al. (2012)
PLP-Fv2E-PERK Normal Normal Normal Lin et al. (2014)
Knockout
Phenotype Demyelination OLG loss Remyelination Microgliosis Astrogliosis Reerence
Act1–/– Less Less Kang et al. (2012)
Axl–/– Less Less Delayed Hoehn et al. (2008)
BDNF+/– More Normal Less Normal Normal VonDran et al. (2011)
Casp1–/– Delayed Delayed Delayed Delayed Jha et al. (2010)
CCL2–/– Normal microgliosis but reduced macrophage inﬁltration Remington et al. (2007)
CCR2–/– Normal microgliosis but reduced macrophage inﬁltration Remington et al. (2007)
CIITA–/– Normal cellular inﬁltration, but no discrimination between inﬂammatory cell types Arancibia-Carcamo et al.
(2004)
COX-2–/– Less Less Palumbo et al. (2011a)
CXCR2–/– Normal Normal Normal Normal Normal Lindner et al. (2008)
CXCR2–/– Less Less Liu et al. (2010a)
CXCR2–/– Accelerated Liu et al. (2010b)
Eif2b5R132H/R132H Less More Geva et al. (2010)
eNOS–/– Normal Normal Delayed Normal Normal Linares et al. (2006)
FcR Fyn–/– Less Less Seiwa et al. (2007)
FGF2–/– Normal Normal More Armstrong et al. (2006,
2002),  Murtie et al. (2005)
Reduced axonal atrophy upon chronic demyelination Tobin et al. (2011)
GAS6–/– More More Delayed Accelerated Binder et al. (2008, 2011)
GnT-IX–/– More Less Kanekiyo et al. (2013)
Golli–/– Less Less Less Less Less Paez et al. (2012)
I-A–/– Less Less Hiremath et al. (2008)
I-Atr Less Less Hiremath et al. (2008)
IFN-R–/– Normal Normal Normal Normal Normal Schmidt et al. (2009)
IFN-–/– Less More Trebst et al. (2007)
IFN-R–/– Less Normal Accelerated Delayed Mana et al. (2006)
IKKCNS–/– Less Less Less Raasch et al. (2011)
IL-17–/– Less Less Kang et al. (2012)
IL-17R–/– Less Less Kang et al. (2012)
IL-18–/– Delayed Delayed More Delayed Delayed Jha et al. (2010)
IL-1–/– Normal Normal Less Normal Normal Jha et al. (2010), Mason
et al. (2001b)
iNOS–/– More More Normal Arnett et al. (2002)
IRF-8–/– Less Less Delayed Horiuchi et al. (2012)
KLF9–/– Less Delayed Dugas et al. (2012)
Lgals3–/– Normal Less Increased Increased Hoyos et al. (2014)
While more microglia are present, they fail to switch to an M2  phenotype
LIF–/– More More Less Marriott et al. (2008)
Lt–/– Delayed Delayed Normal Delayed Normal Plant et al. (2005)
LtR–/– Delayed Delayed Delayed Plant et al. (2007)
MHC-1–/– Normal Normal Normal Arnett et al. (2003)
MHC-2–/– Normal Normal Delayed Arnett et al. (2003)
MIP-1–/– Delayed Delayed Delayed McMahon et al. (2001)
Nlrp3–/– Delayed Delayed Normal Less Delayed Jha et al. (2010)
nNOS–/– Less Less Delayed Less Less Linares et al. (2006)
Noxa–/– Normal Normal Hagemeier et al. (2013)
Olig1–/– Normal Delayed Arnett et al. (2004)
p53–/– Less Less Li et al. (2008)
p75NTR–/– Normal Normal Normal Copray et al. (2005)
p8–/– Delayed Delayed Delayed Plant et al. (2006)
PDGF-R+/– Normal Less Murtie et al. (2005)
Puma–/– Less Less Hagemeier et al. (2013)
RAG1–/– Normal Normal Normal Normal Arnett et al. (2001),
Hiremath et al. (2008)
Sema6–/– Less Bernard et al. (2012)
Sema6+/– Less Bernard et al. (2012)
St8sialV–/– Normal Accelerated Normal Koutsoudaki et al. (2010)
TG2–/– Normal Delayed Normal Van Strien et al. (2011)
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Table  1 (Continued)
Phenotype Demyelination OLG loss Remyelination Microgliosis Astrogliosis Reference
TNF–/– Normal Delayed Less Normal Arnett et al. (2001), Arnett
et al. (2003)
TNFR1–/– Normal Normal Arnett et al. (2001)
TNFR2–/– Normal Less Arnett et al. (2001)
TWEAK–/– Delayed Less Delayed Delayed Normal Iocca et al. (2008)
ER–/– Normal Normal Normal Taylor et al. (2010a)
ER–/– Normal Normal Normal Taylor et al. (2010a)
Conditional knockout
PLP-Notch1–/– Normal Stidworthy et al. (2004)
PLP-1 integrin C Normal Less Lee et al. (2006)
SOCS3MBP/MBP Less Less Emery et al. (2006)
GFAP CreAct1ﬂ/ﬂ Less Less Kang et al. (2012)
GFAP-Thymidine kinase Delayed Normal Less Less Skripuletz et al. (2013)
PLP-CreERT: FGF1ﬂ/ﬂ More Mierzwa et al. (2013), Zhou
et al. (2012)
GFAP-IB-dn Less Less Less Raasch et al. (2011)
IKK2oligo–/– Normal Normal Normal Raasch et al. (2011)
MOGicrefasﬂ/ﬂ Normal Normal Normal Hesse et al. (2010)
Myelin visualization
PLP-eGFP Crawford et al. (2009),
Hussain et al. (2013), Patel
et al. (2013)
CNP-eGFP More More More Millet et al. (2012),
Silvestroff et al. (2010)
Fig. 2. Schematic overview of molecular changes occurring in oligodendrocyte mitochondria following CPZ treatment (affected enzymes are colored in red). These changes,
combined with multiple predisposing factors (colored in yellow), result in an elevated production of ROS/RNS. Dotted lines indicate free diffusion across membranes. Orange
triangles  mark cuproenzymes. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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o the speciﬁc vulnerability of OLGs during this increased oxidative
tress.
The rate of O2•– scavenging and conversion to H2O2 is low in
OLGs as Manganese Superoxide Dismutase (MnSOD) is present
only at low levels (Bernardo et al., 2003; Witherick et al., 2010)
and Copper Zinc Superoxide Dismutase (CuZnSOD), a cuproen-
zyme, has decreased activity during CPZ treatment (Acs et al.,
2013; De and Subramanian, 1982; Ljutakova and Russanov, 1985;
Russanov and Ljutakova, 1980; Zhang et al., 2008).
Glutathione peroxidase (GPx) requires glutathione (GSH) as an
electron donor for the conversion of H2O2 to H2O + O2. OLGs
intrinsically have low amounts of GSH and low GPx activ-
ity (Juurlink et al., 1998; Witherick et al., 2010). Moreover, a
reduction in GSH content was observed during CPZ treatment
(Biancotti et al., 2008).
As an essential trophic factor for ATP production and lipid syn-
thesis, OLGs have a high amount of intracellular Fe sequestered
as Fe3+ inside ferritin. Excess O2•– can however reduce the
sequestered Fe3+ to Fe2+, thereby releasing the latter into the
mitochondrial matrix or cytosol. Subsequently Fe can then
initiate and/or propagate lipid peroxidation through Fenton
chemistry (Juurlink et al., 1998; Marrif and Juurlink, 2003;
Witherick et al., 2010). In vitro, lipid peroxidation can observed by
an increase of malondialdehyde upon treatment of OLG cultures
with CPZ (Xu et al., 2013).
Glycerol phosphate dehydrogenase (GPDH) maintains cellular
redox potential and plays a role in glycerol production, both of
which were found signiﬁcantly increased following CPZ treat-
ment as a consequence of the cell’s response to the increased
oxidative stress (Biancotti et al., 2008).
Peroxisomes, key players in -oxidation and lipid synthesis, pro-
duce high amounts of H2O2 which is normally cleared by GPx
and peroxisome-bound catalase (CAT). In vitro, CPZ was shown to
decrease CAT activity in OLGs cultures (Xu et al., 2013). Addition-
ally, upon OPC maturation the number of peroxisomes increases
signiﬁcantly to allow the OLGs to synthesize the vast amounts of
myelin sheath lipids, thereby increasing the production of H2O2
and thus the degree of oxidative stress (Juurlink et al., 1998).
Metallothioneins (MT) fulﬁll important anti-oxidant functions
(Kang, 2006) and while astrocytes show an increased MT1  and
MT2  expression following CPZ treatment, OLGs express only low
amounts of MTs, which contributes to their oxidative stress vul-
nerability (Biancotti et al., 2008; Witherick et al., 2010).
.3. Perikaryon and myelin sheath degeneration
The above described formation of megamitochondria due to
PZ treatment results in an ATP shortage and increasing ROS/RNS
oncentrations which eventually disrupts proper functioning of
he endoplasmatic reticulum (ER). In this chapter we  discuss how
he combination of oxidative stress and ER stress results in a dis-
urbed protein and lipid synthesis which leads to oligodendrocyte
erikaryon degeneration and myelin sheath disintegration.
ER stress during CPZ treatment is characterized by extensive
roliferation of the ER and a reduction in hydrophobic protein syn-
hesis (Hemm et al., 1971; Love, 1988; Wagner and Rafael, 1977).
R stress also reduces mRNA transcription/translation to prevent
ccumulation of un- or misfolded proteins. As such, the downregu-
ation of myelin protein-related mRNAs can be observed already
ithin the ﬁrst week of CPZ treatment and continues until CPZ
reatment is halted (Arnett et al., 2003; Gao et al., 2000; Gudi et al.,
011; Hesse et al., 2010; Jurevics et al., 2001, 2002; Kipp et al., 2009;
orell et al., 1998; Norkute et al., 2009; Seiwa et al., 2007; Selvaraju
t al., 2004; Skripuletz et al., 2011b; Tansey et al., 1996). However,
isfolded proteins slowly accumulate and eventually trigger thevioral Reviews 47 (2014) 485–505
unfolded protein response (UPR), resulting in a massive release of
calcium into the cytosol and subsequently OLG cell death (Malhotra
and Kaufman, 2007; Matsushima and Morell, 2001; Xu et al., 2005).
Of note, while a re-expression of myelin protein mRNAs can be
observed during OPC inﬁltration in demyelinated areas, this only
results in myelin protein synthesis if CPZ is withdrawn from the
diet (Blakemore, 1984; Ludwin and Sternberger, 1984; Tansey et al.,
1997).
Protein synthesis (and thus correct ER functioning) depends on
the availability of adequate amino acid levels via the plasma, which
in turn depends on correct hepatocyte functioning. As CPZ disturbs
normal hepatic functioning (as observed by hepatic megamito-
chondria), it is no surprise that plasma amino acid levels were
altered during CPZ intoxication. As such, a reduction in the plasma
levels of alanine, proline and glycine was  observed and this trig-
gered the amino acid response pathway (AAR). Activation of the
AAR results in phosphorylation of eukaryotic initiation factor 2 (eIF-
2) which can drive both pro- and anti-apoptotic gene expression
but foremost, results in a strong reduction of mRNA translation and
thus protein synthesis (Goldberg et al., 2013).
Besides the inhibition of myelin protein synthesis, myelin lipid
metabolism is affected as well. The major part of the myelin sheath
(70%) consists out of lipids with more than a third of these lipids
being phospholipids (mainly plasmalogens) that provide structural
support and anti-oxidant functions (Baumann and Pham-Dinh,
2001; Farooqui and Horrocks, 2001). Membrane-bound plasmalo-
gens can be hydrolyzed by plasmalogenase leading to an increase
of free plasmalogens. Phospholipase A2 (PLA2) can degrade both
membrane-bound and free plasmalogens into arachidonic acid
(AA), a key intermediate of pro-inﬂammatory signaling. The activity
of both plasmalogenase and PLA2 is increased during CPZ intox-
ication, thereby contributing to myelin sheath degradation and
elevated concentrations of AA (Carey and Freeman, 1983). More
speciﬁcally, mRNA expression of both secretory PLA2 (sPLA2) and
cytosolic PLA2 (cPLA2), but not calcium-dependent PLA2 (iPLA2), is
increased. However, an increase at the protein level was observed
only for sPLA. Notably, the increase in sPLA occurs at the same time
of microglia and astrocyte inﬂux, indicating their contribution to
the production of sPLA and the creation of a pro-inﬂammatory
environment. Produced AA will then be further metabolized by
cyclooxygenase-1 or -2 (COX-1 and COX-2) into prostaglandin H2
(PGH2). Although both COX-1 and COX-2 mRNA is upregulated dur-
ing CPZ-induced demyelination, only COX-1 expression increased
at the protein level. However, the exact contribution of COX-1
and COX-2 to the CPZ-induced demyelination process is still not
fully unraveled. While COX-1 seemed to be dispensable, COX-2 is
required for effective induction of demyelination, as observed in
COX-1−/− or COX-2−/− mice. PGH2 can give rise to prostaglandin D2
(PGD2), prostaglandin E2 (PGE2), prostacyclin (PGI2) and throm-
boxane (TXB2), which are all detectably increased during the
demyelination process. Moreover, TXB2 production lasted through
subsequent remyelination processes. PGE2 was determined to be
the most robustly increased eicosanoid during demyelination, and
its signaling via the PGE2-EP2 receptor was demonstrated to con-
tribute to OLG apoptosis. The PGE2-EP2 receptor is expressed by
OLGs, astrocytes and microglia and was found upregulated dur-
ing demyelination, indicating that PGE2 could either contribute
directly to OLG apoptosis by EP2 signaling on OLGs or indirectly
through stimulation of pro-inﬂammatory cytokine production by
microglia (Palumbo et al., 2011a,b). Alternatively, 5-lipoxenase
(5-LO) can convert AA into 5-hydroperoxyeicosatetraenoic acid
(5-HPETE), which in turn can give rise to the leukotrienes (LT)
LTA4, LTB4 and LTC4. Although 5-LO expression is increased
during the demyelination process, inhibition of 5-LO does not pre-
vent demyelination despite reduced interleukin (IL)-6 (but not
tumor necrosis factor (TNF)- or IL-1) production by microglia.
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evertheless, these data indicated a role for 5-LO in microglial acti-
ation during CPZ induced demyelination (Yoshikawa et al., 2011).
The other two thirds of the myelin lipid pool consists of many
ifferent lipids, but foremost of cerebrosides (glycosphingolipids)
nd cholesterol, for which the concentration also drastically
ecreases during CPZ treatment. This decrease is in part due to
hagocytosis by microglia/macrophages, but also due to the nor-
al  turnover of myelin sheath lipids (which are not replenished
uring CPZ treatment). Very much the same as for the myelin pro-
ein gene mRNA levels, ER stress causes a drastic decrease in the
RNA levels of the rate limiting enzymes ceramide galactosyl-
ransferase (CGT) for galactocerebroside synthesis and HMG-CoA
eductase for cholesterol synthesis. The mRNA expression of both
GT and HMG-CoA reductase increases again during remyelina-
ion, coinciding with the appearance of endogeneous OPCs in areas
f demyelination (Carey and Freeman, 1983; Jurevics et al., 2001,
002; Morell et al., 1998).
As lipid and protein synthesis are inhibited, honeycomb vesic-
lation of myelin is observed followed by the appearance of
ntramyelinic vacuoles due to ﬂuid accumulation in between
yelin lamellae, thereby splitting these at the intraperiod lines.
luid also regularly accumulates in the periaxonal space resulting
n displacement of the axoplasm, which can cause axonal degener-
tion (Blakemore, 1972, 1973, 1984; Hemm et al., 1971; Kimberlin
t al., 1976; Love, 1988; Ludwin, 1978; Ludwin and Sternberger,
984; Pattison and Jebbett, 1971; Venturini, 1973). Additionally,
utophagocytic and intracytoplasmic vacuoles originating from
isrupted myelin lamellae can be observed (Hemm et al., 1971;
udwin and Sternberger, 1984), along with myelin inner and outer
ongue abnormalities like: (i) a large number of stress ﬁbers, (ii)
embrane bound bodies, (iii) disorientation of microtubuli, and
iv) vacuoles. Although vacuolation alone was demonstrated to be
eversible, demyelination became irreversible following extensive
erikaryon degeneration and ultimately leads to OLG apoptosis
Blakemore, 1984). It is important to note that inner and outer
ongue abnormalities, OLG perikaryon degeneration, as well as
nal OLG apoptosis, precede extensive demyelination during CPZ
ntoxication. This sequence of events is indicative of a primary
egeneration of OLGs, rather than a direct autoimmune-mediated
ttack against myelin proteins. An overview of these degenerative
rocesses is provided in Fig. 3.
.4. Oligodendrocyte apoptosis
The combined oxidative stress and ER stress results in a degen-
rating OLG perikaryon and myelin sheath causing notable OLG
poptosis as early as a few days following initiation of CPZ treat-
ent. In contrast, the massive apoptosis of OLGs by week 4 depends
n the immune system providing a secondary hit to the already
tressed OLGs (see below). Interestingly, by week 6 of CPZ admin-
stration OLGs reappear as OPCs differentiate into OLGs (Dupree
t al., 2004; Goldberg et al., 2013; Gudi et al., 2011; Hesse et al.,
010; Mason et al., 2000b; Morell et al., 1998). On a sidenote, a 3
eek CPZ treatment is sufﬁcient to induce demyelination equal to a
 week treatment. Therefore, once mature OLGs become perturbed,
 sequence of cellular and inﬂammatory events is triggered leading
o OLG apoptosis and demyelination (Doan et al., 2013).
While initially caspase-3 positive fragmented nuclei can be
bserved, during later stages of CPZ intoxication (post week 3)
poptotic OLGs do not have fragmented nuclei and are caspase-3
egative. This suggests a change from caspase-3 dependent apo-
tosis to a caspase-3 independent apoptotic process at the time
f microglial accumulation (Arnett et al., 2002; Hesse et al., 2010).
n addition, while elevated expression of p53, p21 and gadd45 is
bserved during the ﬁrst 3 weeks of CPZ intoxication, which is
ssociated with caspase-3 mediated apoptosis, a reduction in OLGvioral Reviews 47 (2014) 485–505 491
apoptosis is noted in p53−/− mice or upon p53 inhibition (Li et al.,
2008). p53 mediated apoptosis during CPZ intoxication was shown
to be dependent on Puma while Noxa was  shown to be dispens-
able (Hagemeier et al., 2013). Starting from on week 3 post CPZ
administration, an increase in poly ADP-ribose polymerase (PARP)
activation is observed, while caspase-3 expression (which effec-
tively inhibits PARP) is decreased. The upregulation of PARP will
eventually result in apoptosis inducing factor (AIF) mediated apo-
ptosis. In this context, inhibition of PARP was  shown to ameliorate
OLG loss, indicating a clear role for non caspase-3 dependent apo-
ptosis during the later stage of CPZ intoxication (Veto et al., 2010).
On the other hand, several signaling pathways have displayed
protective effects following CPZ intoxication. Leukemia inhibitory
factor (LIF) receptor (LIFR) signaling by LIF and ciliary neurotrophic
factor receptor (CNTF) has been shown to promote OLG survival but
this is usually rapidly terminated by a negative feedback loop medi-
ated by suppressor of cytokine signaling 3 (SOCS3) signaling. As
LIF−/− mice showed drastically accelerated OLG loss and SOCS3−/−
mice showed increased OLG survival after 3 weeks of CPZ intox-
ication, it can be concluded that LIF and CNTF fulﬁll important
anti-apoptotic effect following CPZ intoxication (Emery et al., 2006;
Gudi et al., 2011; Marriott et al., 2008). Another potent survival sig-
nal for mature OLGs is Insulin-like growth factor 1 (IGF-1) which
peaks during week 3 to 4.5 following CPZ intoxication. Transgenic
mice overexpressing IGF-1 where shown to be protected from OLG
apoptosis during CPZ treatment (Gudi et al., 2011; Komoly et al.,
1992; Mason et al., 2000a,b). Recently it has also been shown that
mice overexpressing Galanin (GAL), a bioactive neuropeptide, suf-
fer only very minor demyelination and OLG loss (Zhang et al., 2012).
Summarizing this chapter, current literature attributes CPZ
intoxication to in situ Cu chelation leading to alterations in proper
functioning of many different enzymes. This culminates into an
increased oxidative stress to which oligodendrocytes in particu-
lar are highly sensitive. Next to oxidative stress, CPZ also induces
ER stress and together with reduced amino acid levels, this leads
to disturbed myelin lipid and protein synthesis and eventually into
myelin sheath disintegration. During prolonged increased oxida-
tive stress and ER stress, this process (in combination with a second
hit from the immune system, see below) results in OLG apoptosis,
despite the presence of pro-survival factors.
3. Neuronal pathology
While neuronal pathology following CPZ-induced demyelina-
tion is generally considered to be rare, a body of past and recent
literature indicates the contrary. Early on, changes are noticeable
at the level of the synapse where neurotransmitter concentrations
are disturbed due to alterations in the activity of their synthesizing
enzymes (see Fig. 4). Moreover, in demyelinated regions, axonal
beading can be observed due to inhibited protein transport, which
will eventually lead to axon dystrophy (see Fig. 3). In the follow-
ing section, several aspects leading to neuronal dysfunction and/or
pathology are discussed.
3.1. Neuronal pathology and metabolic coupling between
neurons and astrocytes
Young C57BL/6 mice show minimal axonal loss and no reduc-
tion in neuronal cell number. In aged C57BL/6 mice however, axonal
loss can reach up to 50% and extensive neuron perikaryon degen-
eration was observed in the hippocampus (Hoffmann et al., 2008;
Irvine and Blakemore, 2006). It is however surprising that most
neurons survive acute CPZ intoxication while they are equally
or even more vulnerable to metabolic perturbation as compared
to OLGs. A possible explanation is the metabolic coupling to
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Fig. 3. General schematic overview of the inﬂammatory cascade following CPZ intoxication and how this sequence of events contributes to demyelination, axonal pathology
and  oligodendrocyte apoptosis.
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Fig. 4. Schematic overview of CPZ-induced alterations in neuronal synapses. (A) Metabolic coupling of astrocytes and neurons via lactate shuttling provides TCA substrates
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ABA  concentrations. (B) Inhibition of MAO  and DHB by CPZ results in altered DOP
f  the references to color in this ﬁgure legend, the reader is referred to the web ver
strocytes, protecting neurons from oxidative stress. It is well
escribed that during metabolic stress, astrocytes can initiate gly-
olysis by which the formation of a redox buffer protects neurons
rom oxidative stress (Dewar et al., 2003; Mahad et al., 2008; Marrif
nd Juurlink, 2003).
.2. Disturbance of neurotransmitter homeostasis
A glutamine (GLN)–glutamate (GLU)–gamma aminobyturic acid
GABA) cycle (Fig. 4A) exists between neurons and astrocytes
ecause neurons cannot de novo synthesize GLU or GABA (Bak
t al., 2006). Just like other hydrazines, CPZ has an inhibitory
ffect on Glutamic acid decarboxylase (GAD), leading to energy
hortage and increased GLU concentration, while suggesting a
ecreased GABA concentration (Kesterson and Carlton, 1972). This
ncrease in GLU concentration could be responsible for the observed
ncrease in astrocytic glutamate–aspartate transporter (GLAST)
xpression during demyelination, as astrocytes attempt to keep
LU concentrations at a non-toxic level (Azami Tameh et al., 2013).
euronal expression of -amino-3-hydroxy-5-methyl-4-isoxazole
ropionic acid (AMPA), a GLU receptor, was observed to decrease
uring demyelination and increase again during remyelination.
his process was found to be dependent on microRNA miR-124 and
ight possibly reﬂect a neuronal attempt to limit neurotransmit-
er toxicity during demyelination (Dutta et al., 2013). However, in
ontrast to the previously described decreased GABA concentration
fter 8 weeks of CPZ, a recent study observed an increased GABA
oncentration after 3 weeks of CPZ administration. Although not
ully unraveled, this possibly indicates a change in time in neuro-
ransmitter concentrations during CPZ intoxication (Biancotti et al.,
008).
Dopaminergic and noradrenergic synapses (Fig. 4B) are also
ffected. Dopamine -hydroxylase (DBH), a cupric enzyme that
atalyzes the formation of norepinephrine (NE) from dopamine
DOPA), has a reduced activity during CPZ intoxication. This results
n increased DOPA and decreased NE concentrations, as measured
n the prefrontal cortex (PFC) as early as 2 weeks following CPZ
ntoxication (Herring and Konradi, 2011; Xu et al., 2010). Addition-
lly, monoamine oxidase (MAO), important for clearing excessive
OPA and NE, is also inhibited following CPZ intoxication (De and
ubramanian, 1982; Herring and Konradi, 2011; Venturini, 1973;
akabayashi et al., 1978).
Extraccellular GLU and DOPA can be taken up by OLGs and auto-
xidize by reacting with oxygen, giving rise to their respective
uinones which further reduces anti-oxidant defenses. The highoxidative stress. Inhibition of GAD functioning by CPZ leads to disturbed GLU and
NE concentrations. Enzymes affected by CPZ are colored in red. (For interpretation
f this article.)
Fe concentration in OLGs stimulates this auto-oxidation of neu-
rotransmitters which results in the production of O2•– and H2O2
(Hemdan and Almazan, 2006; Hermida-Ameijeiras et al., 2004;
Hider et al., 2008; Spencer et al., 1998; Stankiewicz and Brass, 2009;
Troadec et al., 2001). Besides uptake of excess neurotransmitters,
OLGs also express GLU receptors like AMPA and kainic acid (KA)
receptors, which can lead to cell swelling and excitotoxic cell death.
Additionally, functional NMDA receptors were also found on myelin
sheaths, thereby allowing Na+ and Ca2+ inﬂux followed by myelin
sheath swelling and vacuolation (Dewar et al., 2003).
3.3. Axonal beading
While short term CPZ intoxication induces synaptic dysfunc-
tion and disturbed neurotransmitter concentrations, long term
CPZ intoxication additionally results in axonal degeneration. Fol-
lowing ﬁring of the neuron, the ATP dependent Na+K+ATPase
repolarizes the nodes of Ranvier. However, as CPZ intoxication dis-
rupts mitochondrial oxidative energy production, which results
in a low ATP supply, Na+K+ATPase functioning might become
inhibited (Campbell and Mahad, 2011; Irvine and Blakemore, 2006).
Combined with a declustering of Na+ and K+ channels following
demyelination, which increases the energy required to repolar-
ize, this will eventually lead to an elevated intra-axonal Na+
and Ca2+ concentration and thus axonal damage (Crawford et al.,
2009; Dupree et al., 2004; Zendedel et al., 2013). In addition,
as voltage-activated K+-channels spread out from their preferred
juxtaparanodal position along the demyelinated axon, a dispropor-
tionate upregulation is noted in the Kv1.1 subunit which results
in a temporal dispersion of the compound action potential (CAP).
The latter provides a ﬁrst mechanistic clue behind the reduction
in excitability of CPZ-induced demyelinated optic nerves (Bagchi
et al., 2014).
A higher intra-axonal Ca2+ concentration disrupts axonal
transport and causes axonal beading due to: (i) enzymatic dephos-
phorylation of NFs which causes NF self-aggregation and (ii), CRM1
dependent translocation to the cytoplasm of histone deacety-
lase (HDAC) HDAC1 (but not HDAC3, HDAC4, HDAC6 or HDAC8),
causing inhibition of axonal transport motor proteins (Kim et al.,
2010). As such, axonal damage was  observed by means of SMI-32
staining while axonal beading was shown via amyloid precursor
protein (APP) staining from week 3 of CPZ treatment onwards
(Crawford et al., 2009; Kim et al., 2010; Lindner et al., 2008;
Merkler et al., 2005; Song et al., 2005; Sun et al., 2006; Tsiperson
et al., 2010; Zaaraoui et al., 2008; Zhang et al., 2011). In contrast,
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yperphosphorylation of the microtubuli-associated protein Tau
as not observed during CPZ intoxication (Schneider et al., 2004).
Supporting a large axon diameter becomes energetically unfa-
orable following demyelination and axonal beading resulting.
s such, a decrease in axon diameter, associated with decreased
xpression of NFs, has been observed after 6 weeks CPZ treatment
Cate et al., 2010b; Wu et al., 2008). Both demyelination and a
ecrease in axon diameter also reduce axonal conduction velocity,
s could be observed for callosally projecting neurons of the deeper
ortex layers, which only partially recovered during remyelination
Bando et al., 2008).
. Involvement of the immune system
While it was recently shown that OLG apoptosis occurs
lready within days following CPZ treatment (thus without exten-
ive microgliosis) (Goldberg et al., 2013), accumulating evidence
rought forward that an additional hit from the immune system is
equired to effectively induce extensive OLG apoptosis by week 4 of
PZ treatment. In vitro, mitochondria and myelin protein synthesis
re affected during CPZ intoxication, and although this eventually
eads to myelin sheath vacuolation, OLGs do not undergo apopto-
is (Cammer, 1999; Pasquini et al., 2007). However, when OLG cell
ultures are treated with CPZ in combination with TNF and/or
FN, they show a signiﬁcant reduction in ETC enzyme activities,
n increased ROS production, and – most importantly – effective
nduction of OLG apoptosis (Pasquini et al., 2007). In vivo, inhibition
f microgliosis by minocycline treatment (Skripuletz et al., 2010)
nd inhibition of neutrophil effector functioning (see below) signif-
cantly reduced OLG apoptosis. Both in vitro and in vivo data thus
ndicate the need for an immune mediated 2nd hit to induce OLG
poptosis. Below, we discuss the role of the immune system dur-
ng CPZ-induced demyelination and the many effector mechanisms
nvolved (see Fig. 3 and Table 1).
.1. Neutrophils
CXCR2+/+ neutrophils inﬁltrate the corpus callosum (CC) already
uring the ﬁrst week of CPZ intoxication and disappear soon there-
fter. Using C57BL/6 CXCR2–/− mice, it was shown that CXCR2+/+
eutrophil inﬁltration was critical to induce OLG apoptosis. Equal
etabolic stress and CD45+/Ly6G+ neutrophil inﬁltration were
bserved between wild type (wt) C57BL/6 and C57BL/6 CXCR2–/−
ice, but only wt mice displayed massive OLG apoptosis. Thus,
n these studies neutrophil accumulation was shown to be inde-
endent of CXCR2, but CXCR2 was critical for neutrophil effector
unctioning (Liu et al., 2010a; Voss et al., 2012). Although these
ndings were in contrast with an earlier study describing equal
emyelination in CXCR2–/− BALB/c mice, the BALB/c background
s known to display only little demyelination upon CPZ intoxica-
ion, making it difﬁcult to observe subtle differences (Lindner et al.,
008).
.2. Astrocytes
Many hypertrophic astrocytes appear at sites where extra-
ellular ﬂuid accumulates from the collapse of intracellular and
ntramyelinic vacuoles. These astrocytes are characterized by
umerous cytoplasmic vacuoles and extensive presence of glial
laments (e.g. GFAP and Vimentin). Their processes are swollen,
atery, pale and devoid of organelles, all indicative of ﬂuid
ptake in an attempt to restore homeostasis (Blakemore, 1972,
973; Hemm et al., 1971; Hibbits et al., 2012; Kesterson and
arlton, 1971; Ludwin, 1978). An increase in astrocytic enzyme
ctivity is noted already 1 week after CPZ intoxication, as
emonstrated by an increased activity of astrocytic glutamatevioral Reviews 47 (2014) 485–505
dehydrogenase (GLDH), NAD(P) diaphorase, lactate dehydrogenase
(LDH), glucose-6-phosphate dehydrogenase (G6PD), Complex II
of the ETC, metallothionein-1 (MT-1), metallothionein-2 (MT-2)
and glutathione-S-transferase (GST) (Cammer and Zhang, 1993;
Kesterson and Carlton, 1971; Tansey et al., 1997; Zatta et al.,
2005). Activation of astrocytes will eventually result in extensive
astrogliosis in the CC by week 4 of CPZ intoxication, and astrogliosis
persists (although less severe) through remyelination. (Chen et al.,
2004; Gudi et al., 2009; Hiremath et al., 1998; Merkler et al., 2005;
Zaaraoui et al., 2008).
Astrocytes can become activated following almost any disturb-
ance of brain homeostasis due to the expression of an enormous
variety of receptors. These activated astrocytes are able to protect
surrounding cells from ATP depletion, oxidative stress and calcium
overload. Moreover, astrocytes maintain CNS ionic homeostasis by
scavenging excess neurotransmitters and secreting neurotrophic
factors which promote cell survival and remyelination (Liberto
et al., 2004; Marrif and Juurlink, 2003; Witherick et al., 2010).
Concerning the latter, expression of the peripheral benzodiazepine
receptor (PBR, also known as TSPO) resulted in mitochondrial
cholesterol uptake, the parent compound for steroid synthesis.
PBR expression peaked by week 4 of CPZ treatment and gradually
disappears thereafter. During remyelination, PBR becomes solely
associated with astrocytes while the microglial expression of PBR
rapidly decays. As a correlation was found between PBR expres-
sion, steroid synthesis and remyelination, astrocytes are thought
to provide trophic support during remyelination. (Chen et al.,
2004; Chen and Guilarte, 2006; Mattner et al., 2011). This assump-
tion is strengthened by the observation that: (i) intraperitoneal
administration of small cholesterol-like compounds, improved
remyelination (Li et al., 2013b) and (ii), progesterone administra-
tion alleviated demyelination and behavioral deﬁcits (Ye et al.,
2013). Another factor corroborating the neuroprotective func-
tion of astrocytes is the increase in retinaldehyde dehydrogenase
(RALDH) expression during CPZ intoxication. RALDH is implicated
in retinoic acid (RA) synthesis, and RA can bind on the RA nuclear
receptor, retinoid X receptor  (RXR), which controls the expres-
sion of many anti-inﬂammatory genes and was found upregulated
speciﬁcally in astrocytes (Konig et al., 2012).
Astrocytic lipidosin expression, involved in -oxidation of fatty
acids, and the production of lipid intermediates, is upregulated
in actively remyelinating lesions following CPZ intoxication (Song
et al., 2007). In addition, many astrocytes positive for brain lipid
binding protein (BLBP), involved in 3 and 6 PUFA uptake by
the cell, are observed in remyelinating lesions. Both these ﬁndings
stress the role of astrocytes in providing trophic support and sub-
strates for myelin sheath synthesis (Kipp et al., 2011). Ceramide is
one of these astrocyte-derived lipid substrates and is de novo syn-
thesized in the ER with serine palmitoyltransferase (SPT) being the
rate-limiting enzyme. During CPZ treatment, astrocytes displayed
increased SPT expression and accumulated intracellular ceramide.
While high concentrations of astrocyte-derived ceramide can sen-
sitize OLGs to apoptotic stimuli, ceramide is also an intermediate
for the synthesis of sphingomyelin, cerebrosides and sphingosine
(Sph). Sph can be further processed into sphingosine-1-phosphate
(S1P) which is implicated in the production of neurotrophic factors
as well as OLG proliferation and survival by binding on S1P recep-
tors. While S1P1 receptor expression by OLGs increases during
demyelination, the aberrant accumulation of ceramides concomi-
tantly decreases S1P production. In this way, a disturbance in
ceramide metabolism might contribute indirectly to OLG apoptosis
(Hu et al., 2011; Kim et al., 2011, 2012).RelA was found activated in astrocytes following demyeli-
nation and both IKK2CNS–/− mice and GFAP-IB-dn mice, but
not IKK2olig–/− mice, showed reduced demyelination following
cuprizone intoxication. This suggested that astrocytes contribute
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o CPZ toxicity in an NF-B dependent way. Additionally, it was
hown that in IKK2CNS–/− mice the expression of IL-1, TNF and
CL2 was reduced, suggesting that NF-B driven pro-inﬂammatory
ene expression in astrocytes might contribute to OLG apoptosis
uring CPZ intoxication (Raasch et al., 2011). Two other possible
ownstream effectors of NF-B signaling, the pro-inﬂammatory
ytokine IL-6 and neuronal NO synthetase (nNOS), were also found
pregulated in astrocytes during CPZ treatment and nNOS, in
ontrast to endothelial NO synthethase (eNOS), was shown indis-
ensable for CPZ induced OLG apoptosis (Linares et al., 2006;
ezuka et al., 2013). In contrast to the above described delete-
ious role for NF-B signaling during CPZ treatment, astrocytes
ecome ADAM12 positive following 5 weeks of CPZ intoxication
n an NF-B-dependent way. This suggests a dual role for NF-
B signaling in astrocytes, as ADAM12 modiﬁes the extra cellular
atrix (ECM) to allow OPC inﬁltration (Baertling et al., 2010).
ext to ADAM12, astrocytes were also shown to modify the ECM
ia O-mannosylation of -dystroglycans, which was  catalyzed by
cetylglucosaminyltransferase-IX (GnT-IX). However, in contrast
o ADAM12, O-mannosyl glucans are inhibitory to remyelination
Kanekiyo et al., 2013).
.3. Microglia/macrophages
A key study by Hiremath et al. (1998), in which demyelination
as induced for the ﬁrst time in C57BL6/J mice using CPZ, also
escribed extensive microgliosis following CPZ treatment. As such,
icrogliosis was seen as early as week 2 and peaked by week 4.5,
oinciding with massive demyelination and initiation of remyeli-
ation. At the peak of microgliosis a large number of proliferating
icroglia can be observed, although up to 30% of these originate
rom peripheral progenitors that had adopted a microglial pheno-
ype after lesion inﬁltration (Hiremath et al., 1998; Matsushima and
orell, 2001; Remington et al., 2007). The inﬁltration of peripheral
acrophages is dependent on the CCR2/CCL2 signaling axis, and
CL2 mRNA expression was upregulated during early CPZ intoxica-
ion (Biancotti et al., 2008). However, as microglia and macrophages
re phenotypically largely the same, and literature rarely discrim-
nates between the 2 cell populations, we here refer to microglia
nd/or macrophages as microglia, unless stated otherwise.
Microglia within CPZ-induced lesions have been ascribed both
 pro-inﬂammatory M1  and an anti-inﬂammatory or regenera-
ive M2  phenotype. The temporal co-existence of both phenotypes
f microglia was supported by the detection of differentially
xpressed receptors and cytokines, like TLR-4, Lyz2, TNF-, IL-
, IL-1 and MMP12 indicative for M1  phenotype, and IL-13R1,
L-4R and IL-2R indicative for M2  phenotype (Arnett et al.,
003; Olah et al., 2012). Importantly, it was shown that myelin
ebris has a regulatory effect on microglial activation, phagocyto-
is and thus remyelination (Kotter et al., 2006; Skripuletz et al.,
013), and microglia have been shown to change their pheno-
ype during myelin phagocytosis toward the anti-inﬂammatory
nd neurogenesis-stimulating M2 phenotype (Neumann et al.,
009). Additionally, based upon their transcriptome ﬁngerprint
icroglia exert the following functional tasks: (i) phagocytosis of
yelin debris and dead cells, (ii) salvage of myelin constituents,
iii) recruitment of OPCs and trophic support, and (iv) orchestrat-
ng tissue remoddeling (Biancotti et al., 2008; Matsushima and
orell, 2001; McMahon et al., 2002; Olah et al., 2012; Voss et al.,
012). As such, microglia are observed at sites of myelin vacuola-
ion where they phagocytize excess ﬂuids and myelin debris. It has
o be noted however, that several authors also reported the occur-
ence of microglial processes in between myelin lamellae, stripping
yelin from axons, indicating that microglia might actively take
art in myelin breakdown (Blakemore, 1972, 1973; Ludwin, 1978).
his process might be driven by the upregulation of the p8vioral Reviews 47 (2014) 485–505 495
transcription factor, resulting in the expression of matrix metal-
loproteinases (MMPs) and MMPs  are known to stimulate myelin
sheath degradation. Additionally, tissue inhibitors of metallopro-
teinase (TIMPs) are able to inhibit MMPs, and a disturbance of the
balance between MMPs  and TIMPs has also been noted during CPZ
intoxication (Plant et al., 2006; Skuljec et al., 2011).
During CPZ intoxication, microglia in demyelinating lesions dis-
play an upregulation of phagocytosis-related proteins and signaling
molecules, including lysozyme, triggering receptor expressed on
myeloid cells-2 (TREM-2b), CD11b, CD80, toll like receptors (TLRs),
FC receptors (FcR), phosphatidylserine receptors (PSRs), scavenger
receptors (Srs), complement receptors (Crs) and purine receptors
(Prs). As discussed before, the increased phagocytic activity by
microglia was subsequently followed by the upregulation of mRNA
for myelin-related genes, like MBP  and MAG, once more supporting
the fact that microglial myelin debris phagocytosis allowed OPCs
to initiate differentiation and remyelination (Bedard et al., 2007;
Jurevics et al., 2002; Matsushima and Morell, 2001; Morell et al.,
1998; Voss et al., 2012). Myelin debris phagocytosis was  shown
to be, at least partially, dependent on C3a or C5a deposition, indi-
cating a clear role for complement proteins during myelin debris
phagocytosis (Ingersoll et al., 2010). During demyelination, deposi-
tion of C1q protein was also noted while the expression of soluble
Crry protein was  abolished, facilitating the complement-mediated
myelin debris phagocytosis by microglia (Briggs et al., 2007). Addi-
tionally, osteopontin expression peaks by week 3 of CPZ treatment
and was also shown to facilitate myelin debris phagocytosis. While
the exact mechanism is still unknown, osteopontin was speculated
to function as an opsonin (Selvaraju et al., 2004).
As CPZ induces demyelination without T cell involvement, MHC-
II expression in this model is directly associated with microglia
activation. Defective MHC-II signaling results in reduced microglial
TNF, IL-1 and NO production (Arnett et al., 2003; Bedard et al.,
2007; Hiremath et al., 2008; Voss et al., 2012). Additionally, Class
II transactivator (CIITA) was shown to effectively control (but
not restrict) MHC-II expression during the different stages of CPZ
induced demyelination (Arancibia-Carcamo et al., 2004). Of note,
although MHC-II was  not responsible for antigen presentation, a
sub population of microglia was found to express CD11c, a marker
for antigen presenting cells in the peripheral immune system. In
in vitro experiments, this subpopulation displayed high expression
of MHC-I, CD80 and CD86, resulting in strong antigen presenting
capabilities (Remington et al., 2007).
The activation of microglia is partially also mediated via astro-
cytes, providing the necessary signaling environment to trigger
microglia recruitment and subsequent myelin debris phagocyto-
sis, a process possibly mediated by CXCL10 signaling (McMahon
et al., 2001; Skripuletz et al., 2013). In addition, microglial MIP-
1 and MIP-1 expression peaked by week 4 of CPZ treatment
as such, microglia themselves amplify microglial accumulation
and activation (McMahon et al., 2001). On the other hand, the
latter could for example also be responsible for astrocytic IL-6 pro-
duction as described earlier. Microglia also express a wide range
of danger-associated molecular patterns (DAMPs) which allow
them to sense the CPZ induced metabolic stress and subsequently
become activated. Following CPZ treatment, microglial DAMP acti-
vation triggers an increase in NLRP3 inﬂammasome formation, and
subsequently an increase of caspase-1 activation and the produc-
tion of IL-1 and IL-18. Where NLRP3, caspase-1 and IL-18 were
shown necessary for demyelination, IL-1 was shown to be dis-
pensable despite being present at elevated concentrations during
CPZ-induced demyelination. In contrast, where IL-18 was  shown
detrimental for remyelination, IL-1 was  shown to be an important
factor in promoting remyelination (Jha et al., 2010; Mason et al.,
2001b). Lastly, growth arrest-speciﬁc protein 6 (GAS6) signals via
its receptors Tyro3, Mer  and Axl. Microglial Axl (but not Tyro3)
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ignaling was shown important for microglia accumulation and
hagocytosis of myelin debris during CPZ treatment. In contrast,
yro3 expression by OLGs was shown an important pro-survival
ignaling pathway, and absence of GAS6 signiﬁcantly delayed
emyelination following CPZ induced demyelination (Binder et al.,
008, 2011; Hoehn et al., 2008; Tsiperson et al., 2010).
As a major microglial effector molecule, TNF readily induces
poptosis in CPZ treated OLG cultures, consistent with TNF
ignaling via TNFR-1 (Pasquini et al., 2007). However, while the
poptosis promoting TNFR-1 is found constitutively on OLGs,
n upregulation of TNFR-2 on OLGs was seen during de- and
emyelination, thereby promoting OLG survival. These data clearly
ndicate a dual role for microglial TNF signaling during de- and
emyelination (Arnett et al., 2001; Plant et al., 2005). Addition-
lly, it was recently shown that TNFR-2 activation on astrocytes
s required for astrocytic CXCL12 production, which then binds
n CXCR4 expressed by OPCs and by doing so induces OPC pro-
iferation and differentiation (Patel et al., 2012). Another member
f the TNF superfamily, lymphotoxin- (LT), is mainly produced
y astrocytes and was shown to be extremely toxic to OLGs
n vitro while delaying OLG loss and subsequent microglial accu-
ulation following CPZ treatment (Plant et al., 2005; Voss et al.,
012). Upon interaction of LT with LT within astrocytes, LT
s then able to bind the microglial LT receptor (LTR). During
PZ induced demyelination, LTR expression by microglia was
ncreased and LTR signaling contributed to demyelination in an
F-B dependent way (Plant et al., 2007). A third cytokine of the
NF superfamily, TNF-like weak inducer of apoptosis (TWEAK),
an exert both pro- and anti-apoptotic functions by binding to its
eceptor Fn14. Expression of Fn14 was found to be signiﬁcantly
pregulated on astrocytes following CPZ treatment, and TWEAK
as suggested to contribute to demyelination by stimulation of
icroglia accumulation (Iocca et al., 2008).
As a second major effector pathway, microglia produce high
mounts of AA metabolites, NO and ROS in response to injury
Liberto et al., 2004). While astrocytic/neuronal nNOS was  shown to
e crucial for the induction of OLG apoptosis (see above), activated
icroglia produce substantial higher amounts of NO via inducible
OS (iNOS) and iNOS becomes rapidly upregulated in microglia
uring CPZ intoxication. Rather unexpectedly however, iNOS was
ound to protect against demyelination and OLG loss at week 3, but
ot week 4, of CPZ treatment. This effect might be due to the iNOS-
egative feedback system which normally limits pro-inﬂammatory
ytokine expression and compensatory effects of eNOS. These data
uggest that effector function(s) of NO might depend on the source
nd concentration of NO during CPZ intoxication (Arnett et al.,
002; Raposo et al., 2013).
.4. T and B cells
A leaky blood brain barrier (BBB) is one of the hallmarks of MS
athology as it allows entry of inﬂammatory cells, among which
uto-reactive T cells, into the CNS. However, during CPZ intoxica-
ion an intact BBB was shown by HRP leakage, radioactive tracer
eakage, serum extravasation and MRI, thereby in part explaining
he absence of T and B cell contribution to CPZ induced pathology
Bakker and Ludwin, 1987; McMahon et al., 2002; Merkler et al.,
005; Sansom et al., 1973). Moreover, using RAG/− mice, deﬁcient
n B and T cells, it has been shown multiple times that, in contrast to
AE, B and T cells do not contribute to CPZ induced lesions, as equal
emyelination was observed in wt and RAG–/− mice (Arnett et al.,
001; Hiremath et al., 2008; Hiremath et al., 1998; Matsushima and
orell, 2001). During CPZ intoxication, lymphocytes were only a
ery small fraction (1.5%) of the inﬁltrating peripheral cell popu-
ations (McMahon et al., 2002; Remington et al., 2007). Inﬁltrating
 cells displayed a non-activated phenotype, as determined by thevioral Reviews 47 (2014) 485–505
absence of CD44 and CD69 expression (Remington et al., 2007).
Additionally, as Cu is required for IL-2 synthesis, it is no surprise
that IL-2 mRNA expression is not observed during CPZ intoxication.
However, IL-2 has chemoattractant properties and is important for
proliferation of activated T cells and as such, the lack of IL-2 can at
least partially explain the absence of a contributing T-cell compo-
nent during CPZ intoxication (Matsushima and Morell, 2001).
However, it is important to note that CPZ-induced demyelina-
tion can lead to the generation of myelin reactive T and B cells.
For example, myelin speciﬁc humoral responses were observed
after CPZ-induced demyelination. Moreover, T cells isolated from
CPZ treated animals were shown to display decreased IFN- and
TNF- expression, but an increased IL-10 expression upon stimu-
lation with myelin antigens. In vivo, resistance to EAE induction was
shown upon extensive CPZ induced demyelination. These in vitro
and in vivo experiments suggest that CPZ treatment triggers a
series of regulatory mechanisms, which drives T cells toward tol-
erance rather than encephalitogenicity (Mana et al., 2009). Indeed,
as described earlier, microglia upregulate their machinery for anti-
gen presentation (MHC-II, CD74, class H2-A and class HZ-A1),
however the expression levels of co-stimulatory molecules, like
CD40 and CD80, remains unchanged on most microglia. Moreover,
the inhibitory costimulatory molecule CD247 becomes upregulated
(Olah et al., 2012). Recently it was shown that, following NLRP3
inﬂammasome-mediated IL-1 and IL-18 production by microglia,
CD3+ T cells produce IL-17 and in this way amplify the inﬂammatory
cascade. As deﬁcient IL-17 signaling resulted in a reduced demyeli-
nation following CPZ treatment, this might indicate a possible role
for T cells during CPZ intoxication after all (Kang et al., 2012).
Finally, the role of interferon gamma  (IFN-), a major pro-
inﬂammatory cytokine produced by T cells and natural killer cells,
and one of the most potent activating stimuli for macrophages
and microglia, is rather unclear at the moment. IFN- receptor
(IFN-R)–/− mice and Irf8–/− mice, a downstream effector of IFN-
receptor signaling, both displayed delayed microglia accumulation
and demyelination, in combination with increased OLG  survival,
indicating an important role for IFN- during non T-cell medi-
ated demyelination (Mana et al., 2006). However, transgenic mice
expressing IFN- under control of the MBP  promotor displayed
reduced astrogliosis, microgliosis, OLG apoptosis and demyelina-
tion during CPZ intoxication (Gao et al., 2000). Therefore, further
research will be needed to determine the exact contribution of
IFN- signaling to neuroprotection and/or neuroregeneration.
Summarizing this chapter, we here described multiple immune
effector systems following CPZ induced metabolic changes. Impor-
tantly, neutrophils are observed inﬁltrating the CNS lesion already
after 1 week of CPZ treatment, and together with microglia are the
main inducers of OLG apoptosis. However, astrocytes and microglia
display a rapid reaction to metabolic perturbations and attempt
to restore homeostasis by clearance of cellular/myelin debris and
excess ﬂuids. In this context, the removal of myelin and cellular
debris is an important pre-requisite for remyelination to occur. In
addition, the secretion of neurotrophic factors by immune cells
is indispensable for remyelination effective remyelination (see
below).
5. Remyelination
Remyelination starts at the onset of OPC accumulation and this
coincides with the accumulation of microglia and astrocytes follow-
ing 3 weeks of CPZ treatment. Subsequently, myelin protein mRNA
expression is upregulated by week 5, when OPCs start differentiat-
ing. Remyelination becomes apparent by week 6 of CPZ treatment
as the newly formed OLGs become mature, myelinating OLGs
(Mason et al., 2000a; Matsushima and Morell, 2001; Skripuletz
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t al., 2011a). This temporal coincidence suggests a link between
nﬂammation and remyelination, which is further supported by the
act that remyelination in wild type mice is much more effective as
ompared to remyelination in TNF–/− and MHC-2–/− mice follow-
ng CPZ-induced demyelination (Arnett et al., 2003). This link can
lso be speculated from a growth factor expression analysis dur-
ng CPZ intoxication. NRG1, GDNF and CNTF are upregulated early
n and thought to induce astrocytic LIF production, which in turn
ctivates microglia to release IGF-1, FGF2, and HGF (Gudi et al.,
011). Additionally, microglia were shown important for an efﬁ-
ient remyelination process as microglia inhibition via minocycline
reatment prohibited microglial CNTF production, and eventually
ampered remyelination (Tanaka et al., 2013).
Paradoxically, OPCs survive during CPZ treatment while they
re more susceptible to oxidative stress as compared to mature
LGs. Although OPCs express higher levels of O2•– scavenging
nSOD, they display an estimated 8 fold less H2O2 scavenging CAT
ctivity as compared to OLGs (Bernardo et al., 2003; Butts et al.,
008). Nonetheless, OPCs themselves survive CPZ treatment as
heir metabolism is much slower compared to mature OLGs. Upon
ifferentiation however, the newly formed OLGs become subjected
o a much higher oxidative stress and ER stress as they attempt
o synthesize the vast amounts of proteins and lipids required to
roduce the myelin sheaths, and this eventually results in the cell
eath of these newly formed OLGs (Benardais et al., 2013; Butts
t al., 2008; Juurlink et al., 1998). As such, during remyelination, ER
tress was only observed in newly formed OLGs by the expression
f binding immunoglobulin protein (BiP), CAATT enhancer-binding
rotein homologous protein (CHOP) and eIF-2. Binding of the ER
haperone BiP to misfolded proteins will release BiP from PERK and
ventually results in the phosphorylation of eIF-2. The latter then
auses attenuation of mRNA transcription and the initiation of the
PR as the cell tries to survive. However, when ER stress cannot be
esolved due to continuous CPZ treatment, the UPR will result in
HOP expression and thus eventually OLG apoptosis. Of note, PERK
verexpression was found to potently protect remyelinating OLGs
rom the deleterious effects of IFN- (Lin et al., 2006, 2014). Lastly,
nhibition of the 26S proteasome was seen to result in an arrest of
PC proliferation and stimulated their differentiation (Millet et al.,
009; Pasquini et al., 2003).
The OPCs found in demyelinated lesions can be either endo-
eneous to the tissue, originate from nearby unaffected tissue
r originate from germinal locations like the subventricular zone
SVZ), the subcallosal zone (SCZ) or the hippocampal subgranular
one (SGZ). Proliferating OPCs are observed in demyelinated lesions
etween week 1 and 5 of CPZ administration, but also in the afore-
entioned germinal zones from which OPCs are thought to migrate
oward the demyelinating lesions (Islam et al., 2009; Kumar et al.,
007; Mason et al., 2000a; Murtie et al., 2005; Silvestroff et al.,
010; Vana et al., 2007; Woodruff et al., 2004). For the SVZ in
articular, an increased progenitor cell proliferation in response
o CPZ treatment was observed, but these cells accumulated in
he olfactory bulb rather than the splenium following CPZ-induced
emyelination. Therefore, this study supported the notion that it
s most likely tissue endogeneous OPCs which are responsible for
he spontaneous remyelination (Guglielmetti et al., 2013). Inter-
stingly, under demyelinating conditions where OLGs survive, no
PC accumulation is observed, indicating that OLG apoptosis, but
ot demyelination, is a necessary trigger for OPC accumulation to
ccur (Mason et al., 2000b).
During development, myelination occurs following a strict
rowth factor expression scheme which ﬁnally results in the for-
ation of myelinating OLGs (Trapp et al., 1997). The same is true for
emyelination following CPZ treatment although differences can be
oted. As such, remyelination is initiated by the proliferation and
igration of OPCs toward the lesion site. This process, at least invioral Reviews 47 (2014) 485–505 497
the CPZ model, was shown to be dependent on signaling by golli
myelin basic protein (Paez et al., 2012), T3 hormone dependent
gene expression (Franco et al., 2008; Harsan et al., 2008; Silvestroff
et al., 2012) and the stimulation by BDNF (Gudi et al., 2011; VonDran
et al., 2011). In contrast, CXCR2 signaling by non-hematopoietic
cells was  shown to be deleterious to OPC lesion repopulation as
CXCR2–/− mice displayed improved OPC distribution (Liu et al.,
2010b).
Following the accumulation of OPCs at demyelinated lesions,
OPCs will start to differentiate toward OLGs and many proteins
and transcription factors were seen to play a role in this process.
As such, the transcription factor Olig-2 and its downstream effec-
tor Zinc ﬁnger protein 488 (Zfp488) were observed to be critical to
OPC differentiation into OLGs (Chen et al., 2012; Soundarapandian
et al., 2011). Kruppel-like factor 9 (Klf9), another zinc ﬁnger con-
taining transcription factor, is induced by the earlier mentioned T3
hormone, and was  also shown required for efﬁcient differentiation
of OPCs into OLGs (Dugas et al., 2012). In addition, ECM modiﬁ-
cation by tissue transglutaminase (tTG) was  shown important for
OLG process elongation and branching (Van Strien et al., 2011). In
contrast, posttranslational modiﬁcation of the neural cell adhesion
molecule (NCAM) by polysialic acid (PSA, synthesized by St8siaIV)
(Koutsoudaki et al., 2010), or the expression of LINGO-1 were seen
to inhibit OPC differentiation toward OLGs (Mi  et al., 2009). When
LINGO-1 dimerizes with p75NTR in the presence of myelin pro-
teins, they are known to inhibit neurite outgrowth (Lu et al., 2005)
but the effect of only p75NTR signaling on remyelination remains
unknown and requires further investigation (Petratos et al., 2004).
Besides the critical importance of the above mentioned factors, the
necessity of several immune-cell derived molecules and proteins
for OPC differentiation has also been shown. As such, the microglial
expression of galectin 3 was  shown critical to OPC differentiation.
Whether this was due to a direct effect on OLGs or the induction
of microglia to adopt an M2  phenotype (or a combination of both)
remains to be elucidated (Hoyos et al., 2014; Pasquini et al., 2011).
Additionally, the major microglial effector molecule GLU has its
NMDA receptor expressed by NG2+ OPCs and was  shown necessary
for OPC differentiation (Li et al., 2013a). Lastly, CXCL12 signaling via
CXCR4 on OPCs also induced OPC differentiation. As astrocytes pro-
duce CXCL12 in human MS  lesions, these authors hypothesized that
astrocytes might be responsible for CXCL12 production during CPZ
treatment as well, but this remains to be proven (Patel et al., 2010).
The last part of the transcriptional program during remyelina-
tion covers the maturation of these newly formed OLGs into fully
mature, myelinating OLGs. A large portion of the newly formed
OLGs is positive for the transcription factor SOX17, but SOX17
expression is lost once OLGs are fully mature. This suggested that
SOX17 is an important initiating factor of OLG maturation (Moll
et al., 2013). Another transcription factor, Olig-1, is known to pro-
mote OLG process elongation and branching (Othman et al., 2011),
and was shown to contribute to OLG maturation during remyelina-
tion (Arnett et al., 2004). Lastly, the presence of BDNF (Gudi et al.,
2011; VonDran et al., 2011) and IL-11 (Maheshwari et al., 2013)
were shown to promote OLG maturation, while galectin 1 inhibited
OLG maturation (Pasquini et al., 2011).
While the above described factors thus have a straightforward
function during remyelination, some proteins were seen to exert
a dual function or even a not yet fully elucidated function. As such,
FGF2 signaling via FGF receptor 1 was  attributed a dual function
as it was  shown to stimulate OPC proliferation but to inhibit dif-
ferentiation into myelinating OLGs (Armstrong et al., 2006, 2002;
Gudi et al., 2011; Mierzwa et al., 2013; Tobin et al., 2011; Zhou
et al., 2012). In addition to FGF2, PDGF- signaling was found to
stimulate OPC proliferation but also contributed to the maturation
of OPCs into myelinating OLGs. Therefore it was proposed that
while PDGF- is critical to OPC proliferation and accumulation,
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GF2 is synergistic the PDGF- mediated accumulation of OPCs
s it prevents further maturation of OPCs into OLGs (Kumar et al.,
007; Murtie et al., 2005; Vana et al., 2007; Woodruff et al., 2004).
one morphogenic protein 4 (BMP4) exerted a dual function
s well, as it stimulated OPC proliferation while inhibiting OPC
ifferentiation. As a sidenote, BMP4 apparently also fulﬁlled a role
uring demyelination, as the phosphorylation of its downstream
ffector proteins SMAD1, SMAD5 and SMAD8 indicated active
MP4 signaling (Cate et al., 2010a; Sabo et al., 2013, 2011). The
ro-inﬂammatory IL-1 on the other hand, was shown redundant
or demyelination while it stimulated IGF-1 production and in
his way contributed to remyelination (Komoly et al., 1992;
ason et al., 2001b; Matsushima and Morell, 2001). Unexpectedly,
agged 1 (Stidworthy et al., 2004) and semaphorin 6A (Bernard
t al., 2012) did not inﬂuence any stage of the remyelination
rocess.
Following the above described initial spontaneous attempt
t remyelination, and during continued CPZ treatment, a 2nd
ave of OLG apoptosis is noted around week 8 which is again
uickly followed by another spontaneous attempt at remyelina-
ion starting between week 10 and 12. However, this 2nd attempt
s much smaller in comparison with the observed remyelina-
ion after acute demyelination. The latter can be explained by:
i) depletion of the OPC population, (ii) the presence and/or
bsence of respectively inhibitory and/or stimulatory signals for
PC proliferation and differentiation, and (iii) the inability of
PCs to migrate into the lesions due to the absence of inﬂam-
atory signals triggering cell migration (Biancotti et al., 2008;
lakemore and Irvine, 2008; Kipp et al., 2011; Ludwin, 1980;
ason et al., 2001a, 2004). Additionally, MS  patients shown an
ge-associated decrease in remyelination efﬁciency during subse-
uent demyelinating attacks. This was also observed in the CPZ
odel as older mice show impaired HDAC1 and HDAC2 recruitment
hich results in the accumulation of the transcriptional inhibitors
es1, Hes5, Id2 and Id4 in OPCs following demyelination, and
his will eventually prevent myelin gene expression (Shen et al.,
008).
Therefore, timely remyelination has become an important ther-
peutic goal as it reduces the extent of axonal degeneration (Irvine
nd Blakemore, 2008). Crawford et al. (2009) suggested that for
emyelination to be effective in restoring axonal conduction, a
ritical timewindow exists. As such, when CPZ was  administered
or only 1.5 weeks, no disorganization of the node of Ranvier
as seen and CAPs of callosally projecting neurons were able to
ully recover. However when CPZ was administered for 3 or 6
eeks, node of Ranvier disorganization persisted and CAPs did
ot fully recover, indicating permanent axonal damage. In con-
rast to this, it was recently described that both paranodal and
uxtaparanodal protein organization are nonetheless able to fully
ecover during remyelination (Zoupi et al., 2013). The occurrence
f long lasting deﬁcits is emphasized by the observation that mice
ndergoing demyelination during a 5 week CPZ treatment period,
ully recovered on the motor skill sequence test (MOSS) during
emyelination. However, 28 weeks after the cessation of CPZ intox-
cation, MOSS deﬁcits reappeared (Manrique-Hoyos et al., 2012).
hese apparently contradictory results stress the need for fur-
her research on the long lasting effects of a demyelinating event,
ven when full remyelination has occurred. (Koutsoudaki et al.,
010).
In summary, this chapter describes the key factors modulat-
ng the different stages of remyelination (Fig. 5). Additionally,
espite remyelination to occur spontaneously, it is less effective
n older mice or during subsequent inﬂammatory demyeli-
ating attacks. However, when remyelination occurs outside
he critical time window, long lasting neurological deﬁcits
evelop.vioral Reviews 47 (2014) 485–505
6. Morphological and clinical manifestations after
cuprizone intoxication
CNS demyelination can result in a plethora of clinical symp-
toms dependent on: (i) the area that becomes demyelinated, (ii)
the degree of de- and remyelination, and (iii) the degree and type
of inﬂammation. These major and minor symptoms will be brieﬂy
discussed below.
As described earlier, myelin sheath disintegration occurs
through the formation of many vacuoles and these give rise to
edema and status spongiosus, as characterized by a fragile and less
stiff brain (Carlton, 1966; Ludwin, 1978; Schregel et al., 2012). A
severe edematous midbrain leads to stenosis, or even total occlu-
sion of the aquaduct of sylvius. This causes dilution of the 3th
and lateral ventricles, hydrocephalus and a domed skull from the
resulting pressure (Acs et al., 2009; Hagemeyer et al., 2012; Harsan
et al., 2008; Hoffmann et al., 2008; Kesterson and Carlton, 1970;
Parenti et al., 2010; Stidworthy et al., 2003; Yu et al., 2004). Addi-
tionally, in contrast to the liver, the brain’s dry weight became
irreversibly reduced by a few percentages following CPZ treatment
(Venturini, 1973; Wakabayashi et al., 1975). This reduction in brain
volume/weight was  also characterized by thinning of the CC and
CTX after CPZ intoxication (Fairless et al., 2008; Parenti et al., 2010;
Song et al., 2005).
The earliest clinical observation made in the CPZ model was
that the severity of symptoms and mortality rate was correlated
to the CPZ dose and treatment length (Blakemore, 1973; Carey and
Freeman, 1983; Carlton, 1966; Hiremath et al., 1998; Kesterson and
Carlton, 1970; Ludwin, 1978; Stidworthy et al., 2003). The age of
the mice also had an inﬂuence as weanling mice suffered a very
severe growth reduction and weight loss following CPZ treatment
(Carlton, 1966; Ludwin, 1978). Additionally, older animals were
less susceptible to demyelination compared to juvenile mice, and
thus required higher doses or a prolonged treatment period for
equal pathology to occur (Carlton, 1967, 1969; Pattison and Jebbett,
1971; Wang et al., 2013). The observed weight loss can be explained
by a systemic toxic effect of cuprizone or by a reduced food intake
(Pattison and Jebbett, 1971; Wakabayashi et al., 1975), which also
explains the observed reduction in defecation (Franco-Pons et al.,
2007). On the other hand, diuresis was  increased 10 fold, with urine
having a decreased protein content and increased levels of Cu, Zn
and MTs, indicative of an attempt at metal detoxiﬁcation by MTs
(Kang, 2006; Zatta et al., 2005).
Following CPZ intoxication, mice can display ‘sickness behav-
ior’ which is characterized by weight loss, a general inactivity,
lethargy, anhedonia, altered sleep and sexual patterns (De and
Subramanian, 1982; Ludwin, 1978; Morell et al., 1998; Pattison
and Jebbett, 1971; Petronilli and Zoratti, 1990; Stidworthy et al.,
2003; Suzuki, 1969; Venturini, 1973). A hunched posture, catalepsy
with the nose pushed into the bedding, a ﬂaccid tail and gait abnor-
malities among which ataxia, hind limb paralysis and splayed hind
limbs have also been noticed (Carey and Freeman, 1983; Franco-
Pons et al., 2007; Hemm et al., 1971; Kesterson and Carlton, 1970,
1972; Love, 1988; Ludwin, 1978; Suzuki, 1969; Venturini, 1973;
Wakabayashi et al., 1975). Following 3 weeks of CPZ treatment,
mice display increased activity as observed by increased climbing
behavior (Franco-Pons et al., 2007; Xu et al., 2009). The use of an
adapted MOSS with a complex running wheel reveals motor skill
dysfunction (impaired coordination of leg movement) as the CC
becomes severely demyelinated during CPZ intoxication. Impor-
tant to note is that this functional deﬁcit only partially recovered
during remyelination indicative of long lasting neurological deﬁcits
(Hibbits et al., 2009; Liebetanz and Merkler, 2006). Additionally,
motor coordination impairment was also demonstrated using the
rotarod and beam cross test (Franco-Pons et al., 2007; Hagemeyer
et al., 2012).
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Lig. 5. Schematic overview of the spontaneous remyelination following CPZ-indu
nﬂuencing the different stages of remyelination: migration and proliferation (B), di
ere  shown to stimulate remyelination while factors in red were shown to inhibit 
. Relevance as a model for human diseases
As described above, CPZ intoxication forms an excellent model
o study pathology and/or therapy for human diseases, includ-
ng MS,  epilepsy and schizophrenia. Below we discuss the various
imilarities between CPZ induced CNS lesions and the observed
athologies in human diseases.
.1. Cuprizone as a model for multiple sclerosis
Lucchinetti et al. (2000) published a key study describing
 different lesion subtypes in MS.  Pattern 1 and 2 lesions are
hought to be autoimmune mediated, while both pattern 3 and
 lesions were presumed to be a primary oligodendrogliapathy.
attern 3 lesions in particular display many pathological similar-
ties with CPZ-induced lesions: (i) actively demyelinating lesions
ith little involvement of T cells, but with the presence of many
icroglia/macrophages, (ii) hypoxia-like tissue injury with signs
f metabolic stress and mitochondrial deﬁcits, which eventually
ead to pronounced OLG apoptosis as seen by an upregulation of
53, BCL-2 and FAS, as well as a nuclear translocation of AIF and
ARP, (iii) MAG  mRNA expression is downregulated before other
yelin protein mRNA expression becomes downregulated, and (iv)
ll-deﬁned lesions borders that are not centered around a vein or
enule (Aboul-Enein et al., 2003; Hesse et al., 2010; Li et al., 2008;
ucchinetti et al., 2000; Mahad et al., 2008; Veto et al., 2010). Muchemyelination. Shown is the origin of the accumulating OPCs (A) and the factors
tiation (C) and maturation and myelination (D). Depicted in green are factors which
lination.
like the observed in pattern 3 MS  lesions, CPZ treatment induces
axonal swelling with hyperphosphorylated neuroﬁlaments (SMI-
32) and cytosolic translocation of HDAC1. This axonal swelling
occurs due to a redistribution of Na+ channels along the axon and
mitochondrial deﬁcits which cause a disturbance of Ca2+ and Na+
homeostasis (Kim et al., 2010; Mahad et al., 2008). However, some
differences were also noted as CPZ lesions do display a minimal
presence of (non-contributing) CD3+ T cells and no inﬂamed blood
vessels, as compared to pattern 3 MS  lesions (Kipp et al., 2009;
Komoly, 2005; Liu et al., 2010a).
Motor related symptoms (fatigue, weakness, loss of sight, loss
of balance and loss of speech, muscle spasms, bowel and bladder
incontinence, . . .), cognitive impairments (memory loss, anxi-
ety, social deﬁcits, . . .)  and even seizures have been observed
in MS  patients (Herring and Konradi, 2011). In the CPZ model,
demyelination of the CC has been linked to impaired motor coordi-
nation between left and right paws (Liebetanz and Merkler, 2006).
The degree of hippocampal lesions in MS  correlates to cognitive
dysfunction (especially long-term episodic memory) and severe
demyelination of the hippocampal structure was observed after
CPZ intoxication (Norkute et al., 2009). Demyelination of the basal
ganglia has been linked to MS  symptoms, such as fatigue, memory
and motor skill impairment and extensive demyelination of the
basal ganglia was also seen in the CPZ model (Pott et al., 2009).
Females were shown to be protected from MS attacks during
pregnancy, but relapse rate increased signiﬁcantly during the ﬁrst
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 months post-partum, suggesting an important inﬂuence of sex
teroids. In the CPZ model, estrogen was shown to be an impor-
ant factor contributing to improved remyelination (Patel et al.,
013). Continuous estrogen administration for example was shown
o prevent OLG apoptosis and delayed microglial accumulation
nd demyelination. (Taylor et al., 2010b). OLGs express estrogen
eceptor GPR30 and this receptor was shown to contribute to the
ositive effect of estrogen on remyelination following CPZ-induced
emyelination (Hirahara et al., 2013). Males on the other hand are
nown to be less prone to develop MS  and using the CPZ model it
as shown that testosterone treatment promotes remyelination,
ven following chronic demyelination, and this effect was  medi-
ted via androgen receptor signaling (Hussain et al., 2013). While
he CPZ model has shown the potential of estrogen and testosterone
reatment to promote remyelination, and in contrast to human MS,
o differences in de- and remyelination can be observed between
ale or female C57BL6/J mice following CPZ intoxication. CPZ was
hown to disrupt the estrous cycle and to reduce the weight of male
nd female sex organs, which might affect sex hormone production
Taylor et al., 2010a). On a sidenote, gonadectomized female mice
id show enhanced remyelination compared to gonadectomized
ale mice. As this difference only occurred following gonadectomy,
his stresses the importance of intact sex hormone signaling and
ndicates a sex chromosome gene related effect on the remyelina-
ion process (Moore et al., 2013).
One of the biggest critics on the EAE model for human MS  is
hat numerous developed therapeutics, which displayed beneﬁcial
ffects in this model, are only of little (if any) beneﬁt for the treat-
ent of human MS,  with TNF being the textbook example. TNF
xpression was found to correlate with MS  severity, and inhibition
f TNF signaling ameliorated the EAE course (Klinkert et al., 1997;
artino et al., 1997). In contrast to the EAE model, anti TNF treat-
ent was found to worsen clinical MS  symptoms in MS  patients.
ater on it was shown by Arnett et al. (2001) using the CPZ model,
hat TNF displayed a dual role, where it was required for efﬁcient
emyelination. Other MS  treatment examples are the administra-
ion of glucocorticoids or simvastatin and IFN- treatment and
hese treatments are known to alleviate inﬂammation and reduce
emyelination in MS.  However, using the CPZ model, it was shown
hat these treatments have side-effects regarding remyelination
hich questions their long-term use as a possible MS  treatment
Clarner et al., 2011; Miron et al., 2009; Schmidt et al., 2009; Trebst
t al., 2007). Building upon these experiences, a recently published
tudy investigated the in vivo efﬁcacy of benztropine treatment, an
1 and/or M3  muscarinac receptor antagonist, using both the EAE
odel and the CPZ model. As such, the authors could clearly show
hat benztropine does not affect the immune response but rather
timulates remyelination in both in vivo mouse models (Deshmukh
t al., 2013).
The above described examples are only a few of many stud-
es using the CPZ model to test the efﬁcacy of a certain compound
r treatment in a non-immune mediated, primary oligoden-
ropathy model. In addition, they substantiate the importance of
emyelination as an important therapeutic goal in MS  treatment.
dministration of 0.2% CPZ for 12 weeks induces chronic lesions
ith limited or no remyelination. This failure to remyelinate (often
hile OPCs are still present) is regularly seen in MS  as well. This
ontrol over the length of intoxication, and thus over remyelina-
ion, offers a major advantage over other MS  models (Lucchinetti
t al., 2000).
.2. Cuprizone as a model for epilepsyEpileptic seizures occur in about 3% of MS  patients, but epilepsy
tself is a striking neurodegenerative disease estimated to affect up
o 50 million people worldwide. Similar to epilepsy, CPZ-treatedvioral Reviews 47 (2014) 485–505
mice display tonic-clonic seizures, loss of righting reﬂexes upon
stress inducing stimuli, interictal spikes and frequent spike dis-
charges but high amplitude discharges are rarely observed. While
not completely resolved, possible explanations for the occurrence
of seizures following CPZ treatment are: (i) a decrease in GABA, the
increase in DOPA and the elevated GLU concentrations, ultimately
leading to hyperstimulation, or (ii) demyelination of mossy neu-
rons in the hippocampus leads to the loss of mossy neurons and
thus to hyperexcitability of dentate granule cells (Hoffmann et al.,
2008; Manrique-Hoyos et al., 2012).
7.3. Cuprizone as a model for schizophrenia
In humans, many cognitive functions like spatial working
memory, social interactions, action planning, response inhibition,
decision making and reward processing are mapped to the PFC
and these functions appear altered in schizophrenia patients. As
CPZ induces PFC demyelination, it has been used as a model
for schizophrenia. However, it has to be noted that CPZ induces
widespread demyelination, which does not happen in schizophre-
nia patients (Gregg et al., 2009; Makinodan et al., 2009; Xu et al.,
2009–2011). Genetic studies in schizophrenia patients showed a
down-regulation of genes related to OLGs, myelin and glial cells,
while an up-regulation of stress related genes was found (Gregg
et al., 2009). Multiple MRI  studies also conﬁrmed the involvement
of white matter abnormalities in the PFC of schizophrenia patients
(Xu et al., 2011).
Many of the behavioral alterations in schizophrenia patients
were also found in CPZ treated mice. As such, it was shown that
following CPZ treatment, mice have an impaired spatial memory
(Makinodan et al., 2009; Xu et al., 2009–2011), a decreased thig-
motaxis (Franco-Pons et al., 2007; Makinodan et al., 2009; Xu et al.,
2011, 2009), sensorimotor gating deﬁcits (Xu et al., 2010, 2009) and
a decrease in social behavior like partner grooming, snifﬁng and
mounting (Makinodan et al., 2009; Xu et al., 2009–2011). Concern-
ing social behavior, a reduced CC size (as seen in the CPZ model) has
been implicated with low sociability, possibly reﬂecting the social
withdrawal as observed with schizophrenia patients.
Quetiapine (QUE), an antipsychotic drug commonly used to
treat schizophrenia, prevents CPZ-induced white matter pathology
and behavioral abnormalities as well as promotes remyelination.
This substantiates the link between demyelination and behav-
ioral abnormalities, and the importance of the CPZ model as a
research model for schizophrenia (Chandran et al., 2011; Herring
and Konradi, 2011; Xu et al., 2010; Zhang et al., 2008). Besides
demyelination, other factors are inclined to play a role as not all
behavior abnormalities recover during remyelination (Xu et al.,
2011). Increased DA levels, reduced NE levels and inhibited MAO
and DBH activities were found in the PFC after 2 to 3 weeks of CPZ
treatment, but not after 6 weeks of CPZ treatment. This ﬁts well
within the dopamine hypothesis of schizophrenia, which attributes
the observed gating deﬁcits to disturbed dopamine signaling (Xu
et al., 2010, 2009).
8. Concluding remarks
Ever since its conception, CPZ has been used to study de-
and remyelination in rodents, despite its exact etiology remaining
rather elusive. In this review, we ﬁrst described two potential
physico-chemical modi operandi. Although they appear contradic-
tory, one does not (yet) exclude the other. However, regardless of
its physico-chemical properties, CPZ reliably induces megamito-
chondria in OLGs, ultimately leading to OLG apoptosis. While it
is generally accepted by most authors that CPZ-induced pathol-
ogy originates from metabolic stress, we  here summarized most
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olecular, enzymatic and cellular alterations that result in the
bserved oxidative and metabolic stress. The following section
overed the involvement of neutrophils, astrocytes and microglia
o the initiation and progression of demyelination, but also the
ontribution of ongoing inﬂammatory reactions to remyelination
rocesses. Although multiple molecular pathways involved dur-
ng the observed inﬂammatory reactions are summarized in this
anuscript, it is clear that further research will be necessary to fully
nderstand the mechanism(s) behind CPZ-induced pathology. Full
nderstanding of CPZ-induced pathology will be of utmost impor-
ance to claim the validity of novel MS,  epilepsy or schizophrenia
herapies developed into this model.
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